Evidence-Based Diagnosis and Treatment of Fibromyalgia

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Recognize the presenting symptoms of fibromyalgia
• Conduct a diagnostic workup for patients presenting with fibromyalgia symptoms
• Elucidate the underlying mechanisms of the disease process of fibromyalgia and how these mechanisms tie into presenting clinical symptoms
• Provide pharmacological and non-pharmacological treatments to alleviate the symptoms of fibromyalgia
• Recommend and refer patients to resources within the community to obtain additional knowledge, information, and support for fibromyalgia

Accreditation Information

Physicians: The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. ARHP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Nurses: This educational activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 1.0 contact hour, including 0.5 pharmacology hours. Credit can be applied toward the nursing continuing requirements of most professional organizations and State Boards of Nursing.

Pharmacists: The Association of Reproductive Health Professionals (ARHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hour of continuing education credit. The assigned universal program number for Evidence-Based Diagnosis and Treatment of Fibromyalgia is 463-000-09-009-L04-P.

Others: A certificate of attendance will be issued indicating that this activity is accredited for a maximum of 1 hour of AMA PRA Category 1 Credit^TM.

Sponsoring Information

This program is sponsored by the Association of Reproductive Health Professionals.

Funding Information

This project is funded through an educational grant from Pfizer.

Disclosure Information

All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.

Advisory Committee Disclosures

• Lesley M. Arnold, MD: Receives grants/research support from and consultant for Allergan, Boehringer Ingelheim, Cypress Biosciences Inc., Eli Lilly and Company, Forest, Pfizer, Inc., Sanofi-Aventis, and Wyeth Pharmaceuticals; Consultant for Organon, Sepracor, Takeda, Theravance, UCB, and Vivus, Inc.; Speaker for Eli Lilly and Company, Forest Laboratories, and Pfizer, Inc.
• Anne E. Burke, MD, MPH, FACOG: No affiliations to disclose.
• Daniel J. Clauw, MD: Consultant for Cypress, Forest, Lilly, Pfizer, and Wyeth.
• Kim Dupree Jones, PhD, RN, FNP: Receives grants/research support from Merck and NIH; Consultant for Jazz Pharmaceuticals; Speaker for Forrest, Lilly, and Pfizer, Pharmaceuticals.
• Tieraona Low Dog, MD: No affiliations to disclose.
• Robert Moldwin, MD, FACS: Receives grants/research support from Paragon Biomedical, Pfizer, and Plethora Solutions; Consultant and speaker for Ortho McNeil.
• Anne Moore, MSN, RN-C, FAANP, WHNP: Consultant and speaker for Bayer HealthCare and Duramed Pharmaceuticals; Speaker for Wyeth and P&G.
• Emily Rowe, PharmD: No affiliations to disclose.

ARHP Staff/Consultant Disclosures

• Ellen Cohen, Cert Ed, Dip Ed, CCMEP, Camille Harris, MPH, Beth Jordan, MD, Deborah Shuman, Wayne Shields, and Amy Swann, MA, have no affiliations to disclose.